Pauci-immune glomerulonephritis with ANCA
MONDO:0019988Pauci-immune glomerulonephritis (GN) with antineutrophil cytoplasmic antibodies (ANCA) is a form of rapidly progressive GN comprising about 90% of pauci-immune glomerulonephritis, and associated with the presence of circulating ANCA (mostly directed against proteinase-3 (PR3) and myeloperoxidase (MPO)). Patients usually present with hematuria and rapidly declining renal function, often leading to dialysis within weeks without treatment. Cutaneous, pulmonary, musculoskeletal and nervous involvement may be observed in case of systemic disease, and the correlation between ANCA titer and disease activity has been demonstrated.
Also known as: pauci-immune glomerulonephritis with antineutrophil cytoplasmic antibody
6 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Can a targeted antibody tame kidney inflammation without heavy steroids?
Disease control Not yet recruitingThis phase 2 trial is testing whether a new drug called obinutuzumab beta, combined with a short course of steroids, can help people with newly diagnosed ANCA-associated glomerulonephritis—a rare autoimmune disease that causes kidney inflammation and damage. The study will enroll…
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug STR-P004 aims to tame immune attacks on kidneys
Disease control Not yet recruitingThis early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
A simple blood test may reveal kidney damage in lupus — no biopsy needed?
Diagnosis Not yet recruitingThis study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC